Expression of Interferon Regulatory Factor Family and its Prognostic value in Acute Myeloid Leukemia

Abstract

Aim: To elucidate the clinicopathological and prognostic values of interferon regulatory factor (IRF) family genes in acute myeloid leukemia (AML). Patients & methods: Differential expression analysis and survival analysis from several reliable databases were conducted and further validated using patients with AML. Results: The expression level of IRF1/2/4/5/7/8/9 in patients with AML was upregulated, while IRF3/6 expression was downregulated. High IRF1/7/9 expression indicated a worse overall survival rate. Conclusion: Overexpression of IRF1/7/9 may be associated with poor survival in patients with AML, suggesting that the IRF family may be a promising therapeutic target.

Keywords: :

• acute myeloid leukemia
• bioinformatics integration analysis
• IRF gene family
• prognostic value
• survival

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/fon-2023-0443

Author contributions

Conceptualization: JW Zeng, L Yu, ZF Li and B Xu; data curation: JW Zeng and JW Yao; formal analysis: JW Zeng, L Yu, JW Yao, ZF Li and Y Zhou; funding acquisition: B Xu; investigation: JW Yao, L Zhang and CY Wang; methodology: JW Zeng, L Zhang and B Xu; project administration: B Xu; resources: YM Luo, JW Yao, L Zhang and CY Wang; supervision: B Xu; visualization: JW Zeng and L Yu; writing original draft: JW Zeng; writing, review and editing: JW Zeng, L Yu, JW Yao, YM Luo, Y Zhou and B Xu.

Financial disclosure

This work was financially supported by the National Natural Science Foundation of China (No. 81800196, 81770126 and 81800163), The Natural Science Foundation of Fujian Province (2019J0105,2019J01581) and The Health and Family Planning Young Talents Project of Fujian Provincial (2018-2-63). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.